$5.78 Million in Sales Expected for NewLink Genetics Corp (NLNK) This Quarter

Wall Street brokerages predict that NewLink Genetics Corp (NASDAQ:NLNK) will announce sales of $5.78 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewLink Genetics’ earnings, with estimates ranging from $5.00 million to $7.35 million. NewLink Genetics posted sales of $2.76 million in the same quarter last year, which suggests a positive year over year growth rate of 109.4%. The business is expected to announce its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that NewLink Genetics will report full year sales of $19.37 million for the current fiscal year, with estimates ranging from $18.10 million to $20.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $11.37 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow NewLink Genetics.

How to Become a New Pot Stock Millionaire

NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.32. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. The business had revenue of $10.10 million for the quarter, compared to the consensus estimate of $2.72 million.

NLNK has been the topic of several research analyst reports. Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the stock a “buy” rating in a research note on Friday, March 2nd. Jefferies Group downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Friday, April 6th. Bank of America downgraded NewLink Genetics from a “buy” rating to a “neutral” rating in a research note on Friday, April 6th. Robert W. Baird downgraded NewLink Genetics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $22.00 to $5.00 in a research note on Monday, April 9th. Finally, Stifel Nicolaus restated a “buy” rating and set a $21.00 target price (down from $25.00) on shares of NewLink Genetics in a research note on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $12.86.

A number of hedge funds have recently made changes to their positions in NLNK. Raymond James Financial Services Advisors Inc. acquired a new stake in NewLink Genetics during the 4th quarter worth about $118,000. The Manufacturers Life Insurance Company lifted its position in NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares during the period. Creative Planning acquired a new stake in NewLink Genetics during the 4th quarter worth about $152,000. Acadian Asset Management LLC lifted its position in NewLink Genetics by 241.6% during the 4th quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 13,770 shares during the period. Finally, Raymond James & Associates acquired a new stake in NewLink Genetics during the 4th quarter worth about $240,000. Hedge funds and other institutional investors own 65.05% of the company’s stock.

NLNK stock traded down $0.02 on Tuesday, hitting $4.49. 794,847 shares of the company’s stock were exchanged, compared to its average volume of 1,913,055. NewLink Genetics has a 12-month low of $3.75 and a 12-month high of $19.47. The company has a market cap of $166.83, a price-to-earnings ratio of -1.95 and a beta of 1.22.

WARNING: “$5.78 Million in Sales Expected for NewLink Genetics Corp (NLNK) This Quarter” was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/22/5-78-million-in-sales-expected-for-newlink-genetics-corp-nlnk-this-quarter-2.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply